ZOM

Zomedica Corp

Add to Watchlist

Advanced Chart

0.000

-0.097(-99.692%)1D

Overview
Forecast
Valuation
Earnings

High

Open

VWAP

Vol

Mkt Cap

149.83M

Low

Amount

EV/EBITDA(TTM)

Total Shares

979.95M

18.47M

EV/OCF(TTM)

P/S(TTM)

3.57

Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's Diagnostics segment consists of TRUFORMA products. Its Therapeutics segment consists of PulseVet and Assisi products. Its TRUFORMA Bulk Acoustic Wave (BAW) point-of-care diagnostic platform is marketed with full diagnostic and thyroid panels for dogs and cats that include the only assays of these types available at the point of care to test for feline optimized TSH, endogenous ACTH, Free T4, and quantitative cortisol, along with a total T4 assay. The VetGuardian is its zero-touch vital signs remote monitoring system that enables contact-free, continuous monitoring of a pet's vital signs. The PulseVet is its electrohydraulic shockwave therapy platform. Its Assisi Loop line of products treats pain and inflammation through the delivery of targeted pulsed electromagnetic field focused energy (tPEMF).

0 Analyst Rating

Wall Street analysts forecast ZOM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZOM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

0 Hold

0 Sell

Current: 0

Low

Averages

High

Current: 0

Low

Averages

High

The End

See All Ratings

No Data

Valuation Metrics

The current forward P/E ratio for Zomedica Corp (ZOM.A) is -3.15, compared to its 5-year average forward P/E of -18.44. For a more detailed relative valuation and DCF analysis to assess Zomedica Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.44

Current PE

-3.15

Overvalued PE

27.30

Undervalued PE

-64.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

52.46

Current PS

3.19

Overvalued PS

145.11

Undervalued PS

-40.19